Quanta Appoints New Chief Financial Officer

ALCESTER, England, August 7, 2014 /PRNewswire/ --

Quanta Fluid Solutions Ltd ("Quanta" or the "Company"), a pioneering developer of advanced haemodialysis systems, today announces the appointment of Willem Baralt as Chief Financial Officer.

Willem has almost twenty years of investment banking, executive management and private equity experience. Amongst his achievements, Willem was pivotal in the $1.6billion turnaround and public listing of FLAG Telecom and was co-founder and CFO of Arqaam Capital, one of the largest boutique investment banks based in Dubai. Prior to joining Quanta, he was Managing Director of a private investment office, Mercantile Group.  Additionally, he has also worked at the telecommunications firm Ameritech (SBC), as well the investment banks Deutsche Bank and Panmure Gordon. More recently, he led the acquisition and the subsequent merger of the real-estate agency Humberts with Chesterton. And further, as Deputy Chairman of the enlarged group Chesterton Humberts, Willem oversaw its growth into one of the largest real-estate agencies in the UK and supported its international expansion.

Willem has undergraduate degrees in business administration and computer science from Lehigh University and an MBA from Kellogg Graduate School of Business.

John E. Milad, Chief Executive Officer of Quanta, commented: "We are delighted to have attracted to Quanta someone of Willem's international standing and calibre.  His significant financial and operational experience in multiple markets and across industries will make him an invaluable addition to the management team at this exciting juncture in our Company's development."

Commenting upon his appointment as Chief Financial Officer, Willem Baralt, added: "I am very excited to join John and the rest of the innovative team at Quanta at this pivotal stage for the Company.  Quanta has managed to build a game-changing, world-class, dialysis platform addressing one of the largest healthcare markets.  I am thrilled to support Quanta as we prepare for the clinical introduction of our first product and help transition Quanta into a commercial operation."

About Quanta 

Quanta is developing advanced haemodialysis systems for use in the clinic and the home. The Company's cartridge-based solution SC+ is the only portable, compact haemodialysis system with the clinical efficacy and high flow rates of traditional machines.  SC+ is designed to offer ease-of-use and flexibility, facilitating self-care and supporting dialysis patients across the entire continuum of care.

Quanta is privately owned and based in Alcester, UK.  The Company was founded in 2008 as a spin out from the FTSE 100 engineering company IMI plc, with funding provided by a group of leading venture capital investors specialised in healthcare: NBGI Ventures, Wellington Partners, Seroba Kernel and b-to-v Partners.  

Quanta is dedicated to creating a paradigm shift in renal care and to improving the lives of dialysis patients.

For more information please visit: http://www.quantafs.com

About End Stage Renal Disease and Haemodialysis:  

Lifestyle choices, modern diet and increased life expectancy are all negatively impacting renal health across the globe and End Stage Renal Disease affects millions of patients worldwide. Haemodialysis is a life-saving treatment delivered to an estimated 2 million people globally -with this figure expected to double in the next decade.  

At present, haemodialysis is primarily provided by specialist clinics and centres. However this means that the patient is not in control of when they can dialyse. It is clinically proven that more regular dialysis improves outcomes and quality of life for the patient, and a number of studies have shown that 30-40% of patients would be capable of performing self-dialysis.

Issues of patient benefit, cost and clinic capacity are driving the growth of home and self-care modalities of haemodialysis, but a major factor limiting the growth of self-care and home haemodialysis is the lack of convenient, portable and easy-to-use dialysis systems.  SC+ addresses these issues and puts the patient at the centre, allowing them to take greater control of their treatment.

For more information about Quanta, please contact:
Quanta
John E. Milad,
Chief Executive Officer
T: +44-(0)1789-400043
E: [email protected]

Consilium Strategic Communications
Amber Bielecka/ Mary-Jane Elliott/ Matthew Neal/ Lindsey Neville
T: +44-(0)203-709-5709
E: [email protected]

SOURCE Quanta